2. Academic Validation
  3. Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma

Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma

  • Cancer Res Commun. 2024 Dec 1;4(12):3165-3179. doi: 10.1158/2767-9764.CRC-24-0382.
Yichi Zhang 1,  Marjaana Ojalill 1,  Antonia Boyer 1,  Xiao Lei Chen 1,  Elise Tahon 1,  Gaëtan Thivolle Lioux 1,  Marvin Xia 1,  Maryam Abbas 1,  Halime Meryem Soylu 1,  Douglas B Flieder 2,  Denise C Connolly 2,  Alfredo A Molinolo 3,  Michael T McHale 1,  Dwayne G Stupack 1,  David D Schlaepfer 1
Affiliations

Affiliations

  • 1 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California.
  • 2 Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • 3 Department of Pathology, Moores Cancer Center, University of California San Diego, La Jolla, California.
PMID: 39585085 DOI: 10.1158/2767-9764.CRC-24-0382
Abstract

FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.

Figures
Products